Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium

Inflammatory Bowel Diseases

Volumn 11, Issue 5, 2005, Pages 442-446

  Jacobstein, Douglas A ^a   Markowitz, Jonathan E ^a   Kirschner, Barbara S ^b   Ferry, George ^c   Cohen, Stanley A ^d   Gold, Benjamin D ^e   Winter, Harland S ^f   Heyman, Melvin B ^g   Baldassano, Robert N ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Children's Center for Digestive Health Care   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Infusion reactions

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ABDOMINAL PAIN; ADOLESCENT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; CHILD; CHILDHOOD DISEASE; CHILL; COHORT ANALYSIS; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DYSPNEA; ENTERITIS; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; INFUSION REACTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREMEDICATION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; URTICARIA; VOMITING;

ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, PARENTERAL; MALE; PREMEDICATION; RETROSPECTIVE STUDIES;

EID: 18944367848     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000158166.88238.ea     Document Type: Article

References (13)

1. Present D, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
2. Targan S, Hanauer S, van Deventer SJH, et al. Antibody to tumor necrosis factor in the treatment of Crohn's disease. J Pediatr Gastroenterol Nutr. 1998;27:369-371.
3. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750.
4. Rutgeerts P, Feagan B, Lichtenstein GR, et al. Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn's Disease. Gastroenterology. 2004;126:402-413.
5. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001;7: S17-S22.
6. Kugathasan S, Levy M, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-1414.
7. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol. 2001;96:722-729.
8. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
9. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
10. Cheifitz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
11. Miele E, Markowitz JE, Mamula P et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-508.
12. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84.
13. Stephens MC, Shepanski MA, Mamula P, et al. Incidence of infusion reaction in patients receiving infliximab at a pediatric center. J Pediatr Gastroenterol Nutr. 2001;33:375.